Cancer news source

Filters close
Released: 5-Sep-2024 5:05 PM EDT
Mayo Clinic study finds dysfunctional white blood cells linked to heightened melanoma risk
Mayo Clinic

About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer.

access_time Embargo lifts in 2 days
Embargo will expire: 9-Sep-2024 5:00 AM EDT Released to reporters: 5-Sep-2024 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 9-Sep-2024 5:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Novel Study Reveals How Aging Immune System Fuels Cancer Growth, Potentially Opening New Avenues for Prevention
4-Sep-2024 2:05 PM EDT
Novel Study Reveals How Aging Immune System Fuels Cancer Growth, Potentially Opening New Avenues for Prevention
Mount Sinai Health System

A novel study by researchers at the Icahn School of Medicine at Mount Sinai addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer? The study reveals how an aging immune system spurs tumor growth, offering new insights into cancer prevention and treatment, especially for older adults.

Newswise:Video Embedded ovarian-cancer-what-every-woman-should-know
VIDEO
Released: 5-Sep-2024 12:05 PM EDT
Ovarian Cancer: What Every Woman Should Know
Rutgers Cancer Institute

Ruth D. Stephenson, DO, FACOG, gynecologic oncologist at RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, addresses five frequently asked questions about ovarian cancer.

Newswise: 1920_pancreatic-cancer-study-cedars-sinai.jpg?10000
Released: 5-Sep-2024 11:05 AM EDT
Pancreatic Cancer: Study Finds Most Early Staging Inaccurate
Cedars-Sinai

Staging of patients with early pancreatic cancer is inaccurate as much as 80% of the time, according to a new Cedars-Sinai Cancer study published in the peer-reviewed journal JAMA.

Released: 5-Sep-2024 11:05 AM EDT
Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 for Tissue Repair in Skin Cancer Surgery
Tempo Therapeutics, Inc

Tempo Therapeutics, Inc. ("Tempo"), a leader in tissue engineering and regenerative medicine, has announced the dosing of the first patients in the MOSAIC Trial, a clinical trial for TT101, the company’s lead candidate for tissue regeneration using its proprietary MAP technology.

   
access_time Embargo lifts in 2 days
Embargo will expire: 8-Sep-2024 1:05 PM EDT Released to reporters: 5-Sep-2024 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 8-Sep-2024 1:05 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 5-Sep-2024 9:05 AM EDT
Tip Sheet: 20 years since EGFR discovery, aging and immune function, and immunotherapy leader Dr. Lawrence Fong joins Fred Hutch
Fred Hutchinson Cancer Center

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

access_time Embargo lifts in 2 days
Embargo will expire: 10-Sep-2024 9:00 AM EDT Released to reporters: 5-Sep-2024 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 10-Sep-2024 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal Cancers
3-Sep-2024 1:05 PM EDT
New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal Cancers
National Comprehensive Cancer Network® (NCCN®)

New research just-published online by JNCCN—Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens targeting metastatic GI cancers, it is possible to administer 5-FU solely through continuous infusion, minus the bolus component, without negatively affecting patient outcomes.

Released: 4-Sep-2024 12:00 PM EDT
MD Anderson Research Highlights for September 4, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

   
Released: 4-Sep-2024 11:05 AM EDT
Hackensack Meridian Health Foundation to Honor Peter Cancro and Eli Manning at Annual Gala and Launch Be The Difference Campaign on September 14 at Lincoln Center
Hackensack Meridian Health

Hackensack Meridian Health Foundation to Honor Peter Cancro and Eli Manning at Annual Gala and Launch Be The Difference Campaign on September 14 at Lincoln Center

Newswise: Widespread disparities exist in treating advanced cancers
Released: 4-Sep-2024 11:05 AM EDT
Widespread disparities exist in treating advanced cancers
UT Southwestern Medical Center

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

Released: 4-Sep-2024 11:00 AM EDT
Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy
Moffitt Cancer Center

Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.

Newswise:Video Embedded a-new-artificial-intelligence-tool-for-cancer
VIDEO
29-Aug-2024 5:05 PM EDT
A New Artificial Intelligence Tool for Cancer
Harvard Medical School

The new approach marks a major step forward in the design of AI tools to support clinical decisions in cancer diagnosis, therapy. The model uses features of a tumor’s microenvironment to forecast how a patient might respond to therapy and to help inform individualized treatments.

Released: 4-Sep-2024 10:15 AM EDT
Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in Washington
American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast.

Released: 4-Sep-2024 10:05 AM EDT
PhotonPharma to Present at Rocky Mountain Life Sciences Investor and Partnering Conference
PhotonPharma Inc.

PhotonPharma, a pioneering biotech company focused on innovative cancer therapies, is pleased to announce its selection as a premier presenting company in the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference sponsored by the Colorado BioScience Association.

Released: 4-Sep-2024 10:00 AM EDT
4 Things to Know about Breast Density
American College of Surgeons (ACS)

Radiologists on the National Accreditation Program for Breast Centers (NAPBC) board offer insight into what women should know about breast density and why it matters.


  • Previous Page
  • Next Page

Showing results

11 of 1

close
4.77072